Deutsche Bank Ups Illumina Stock to Buy | GenomeWeb
NEW YORK (GenomeWeb News) — Investment bank Deutsche Bank today upgraded Illumina’s stock to ‘buy’ from ‘hold’ after the company last week reported strong fourth-0quarter revenues but warned of high costs this year.
 
As GenomeWeb News reported last week, Illumina said total revenues for the three months ended Dec. 31, 2006, jumped 163 percent as R&D spending rose 17 percent and profit soared.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.